Startseite The crystal structure of bis(4-(6-carboxy-8-ethyl-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2- yl)piperazin-1-ium) adipate tetrahydrate, C36H52F2N8O14
Artikel Open Access

The crystal structure of bis(4-(6-carboxy-8-ethyl-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2- yl)piperazin-1-ium) adipate tetrahydrate, C36H52F2N8O14

  • Cheng-Jun Jiang EMAIL logo und Ying-Fan Xia
Veröffentlicht/Copyright: 31. Mai 2022

Abstract

C36H52F2N8O14, triclinic, P 1 (no. 2), a = 6.9775(4) Å, b = 9.0785(6) Å, c = 16.8942(10) Å, β = 92.778(2)°, V = 990.91(11) Å3, Z = 1, R gt (F) = 0.0397, wR ref (F2) = 0.1088, T = 170 K.

CCDC no.: 2131232

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colourless needle
Size 0.32 × 0.04 × 0.03 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.12 mm−1
Diffractometer, scan mode: Bruker D8 venture, φ and ω
θmax, completeness: 27.1°, >99%
N(hkl)measured, N(hkl)unique, Rint: 16926, 4372, 0.032
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 3462
N(param)refined: 282
Programs: Bruker [1], Olex2 [2], SHELX [3, 4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z Uiso*/Ueq
F1 0.54391 (18) 0.08485 (10) 0.08471 (6) 0.0433 (3)
O1 0.78452 (16) 0.38446 (12) −0.12696 (6) 0.0286 (2)
O2 0.9589 (2) 0.86045 (14) −0.11739 (8) 0.0439 (3)
O3 0.91400 (18) 0.61436 (14) −0.19045 (7) 0.0349 (3)
H3 0.869493 0.522204 −0.184385 0.052*
N1 0.76033 (17) 0.35227 (14) 0.37883 (7) 0.0213 (3)
H1A 0.665036 0.333659 0.413165 0.026*
H1B 0.882142 0.369992 0.407378 0.026*
N2 0.54156 (19) 0.33030 (14) 0.22750 (7) 0.0238 (3)
N3 0.66426 (17) 0.51109 (13) 0.15404 (7) 0.0199 (2)
N4 0.77448 (17) 0.70845 (13) 0.08743 (7) 0.0209 (3)
C1 0.5295 (2) 0.18633 (17) 0.25458 (9) 0.0261 (3)
H1C 0.509316 0.094903 0.206168 0.031*
H1D 0.413130 0.163290 0.285818 0.031*
C2 0.7214 (2) 0.20890 (17) 0.30832 (9) 0.0244 (3)
H2A 0.709065 0.113885 0.329137 0.029*
H2B 0.835791 0.221342 0.275473 0.029*
C3 0.7582 (2) 0.49702 (17) 0.35203 (9) 0.0244 (3)
H3A 0.872950 0.526568 0.320767 0.029*
H3B 0.772422 0.586740 0.400732 0.029*
C4 0.5625 (2) 0.46521 (18) 0.29861 (9) 0.0254 (3)
H4A 0.447922 0.440893 0.330597 0.030*
H4B 0.562315 0.560574 0.279870 0.030*
C5 0.6047 (2) 0.35929 (16) 0.15643 (8) 0.0202 (3)
C6 0.6043 (2) 0.23981 (16) 0.08407 (9) 0.0244 (3)
C7 0.6601 (2) 0.27632 (17) 0.01412 (9) 0.0234 (3)
H7 0.659342 0.194720 −0.033083 0.028*
C8 0.7197 (2) 0.43658 (16) 0.01162 (8) 0.0202 (3)
C9 0.7176 (2) 0.54752 (16) 0.08445 (8) 0.0193 (3)
C10 0.8334 (2) 0.75503 (17) 0.02061 (9) 0.0233 (3)
H10 0.874117 0.865640 0.024276 0.028*
C11 0.8383 (2) 0.65234 (17) −0.05282 (9) 0.0229 (3)
C12 0.7808 (2) 0.48434 (17) −0.06104 (9) 0.0215 (3)
C13 0.7742 (2) 0.82801 (17) 0.16431 (9) 0.0250 (3)
H13A 0.653363 0.787528 0.190421 0.030*
H13B 0.766842 0.926942 0.150991 0.030*
C14 0.9600 (3) 0.86489 (19) 0.22403 (10) 0.0333 (4)
H14A 1.079962 0.904474 0.198286 0.050*
H14B 0.964654 0.768135 0.239229 0.050*
H14C 0.955917 0.945997 0.273334 0.050*
H6A 0.613 (3) 0.199 (2) 0.6641 (11) 0.050*
C15 0.9083 (2) 0.71961 (19) −0.12192 (10) 0.0293 (3)
O4 0.43462 (15) 0.27607 (12) 0.45897 (6) 0.0269 (2)
O5 0.62103 (16) 0.27011 (13) 0.56760 (7) 0.0312 (3)
C16 0.4586 (2) 0.22506 (16) 0.52098 (9) 0.0209 (3)
C17 0.2825 (2) 0.10104 (17) 0.54002 (9) 0.0241 (3)
H17A 0.318657 0.001184 0.533308 0.029*
H17B 0.264444 0.137634 0.598421 0.029*
C18 0.0825 (2) 0.06374 (17) 0.48852 (9) 0.0263 (3)
H18A 0.098142 0.027198 0.429838 0.032*
H18B 0.041942 0.161861 0.496040 0.032*
O6 0.5790 (2) 0.15812 (16) 0.70852 (8) 0.0443 (3)
H6B 0.664408 0.219882 0.750489 0.066*
O7 1.15544 (15) 0.43331 (13) 0.43775 (7) 0.0312 (3)
H7A 1.238263 0.378885 0.442282 0.047*
H7B 1.222447 0.527083 0.433637 0.047*

Source of material

The mixture of enoxacin (160 mg, 0.5 mmol) and adipic acid (36.5 mg, 0.25 mmol) was dissolved in 8 mL of deionized water. The resulting mixture was stirred and dissolved in a constant temperature water bath at 50 °C to obtain a clear solution, which was filtered and placed in a 10 mL glass bottle. The bottle was sealed with a film with a puncture hole. The filtrate was slowly evaporated at room temperature. Crystal of the title compound were obtained after two days.

Experimental details

Absorption corrections were applied by using multi-scan program [1]. Using Olex2 [2], the structure was solved with the ShelXT [3] structure solution program and refined with the ShelXL [4] refinement package. The H atoms were fixed, fixed Uiso were set to 1.2 times of all C(H) groups, C(H,H) groups and N(H,H) groups; 1.5 times of C(H,H,H,H) groups, O(H) groups and O(H,H) groups.

Comment

As a third-generation quinolone antibiotic, enoxacin has antibacterial effects on Staphylococcus, Escherichia coli, Streptococcus, Helicobacter, etc., which has no cross with other antibiotics [5]. Although enoxacin has good permeability as a BCS class II drug, its solubility is extremely poor, which made it difficult to achieve optimal antibacterial activity. Recently, many studies on quinolone antibiotics with enoxacin-like structures have reported that solubility, permeability and efficacy was improved through the formation of drug salts/co-crystals [6]. For example, the solubility of enrofloxacin with the pharmaceutical salts/co-crystals of maleic, succinic, and oxalic acids was significantly higher, the solubility and stability of the drug [7]. Thus, we believe that the medicinal salt/co-crystal of enoxacin can also be prepared by drug co-crystal technology, which will improve the solubility and permeability of enoxacin and improve the clinical efficacy.

The title crystal was formed by connecting the raw materials enoxacin, adipic acid and water molecules through a protonation/deprotonation reaction of the starting materials followed by crystallisation. The asymmetric unit consists of one monoprotonated enoxacine cation, one half of an adipate and two water molecules. N1H1A in the piperazinium group participates in a classical N1–H1A⃛O4 hydrogen bond to the oxygen atom of the adipate (see the figure). Furthermore the N1H1B in the piperazine group is involved in a N1–H1B⃛O7 hydrogen bond with water molecule (d(N1⃛O7) = 2.7180(16) Å; N1–H1B⃛O7 = 161.5°). Two oxygen atoms in a molecule of the adipate dianion form three hydrogen bonds with two water molecules: O6–H6A⃛O5 (d(O6⃛O5) = 2.7989(17) Å; angle: O6–H6A⃛O5 = 167(2)°); O7–H7A⃛O41(1 = 1 + x, +y, +z; d(O7⃛O4) = 2.7726(15) Å; angle: O7–H7A⃛O4 = 174.9°); O7–H7B⃛O52 (2 = 2−x, 1−y, 1−z; d(O7⃛O5) = 2.7340(15) Å; angle: O7–H7A⃛O5 = 175.5°). Bond lengths and angles derived from the title crystal structure are in the expected ranges.


Corresponding author: Jiang Cheng-Jun, School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Liuhe Road 318#, Hangzhou, China, E-mail:

Award Identifier / Grant number: LGJ20B060001

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This research was supported by the Zhejiang Province Basic Public Welfare Research Project (LGJ20B060001).

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Bruker. Apex3 v. 2016.9-0 and SAINT v. 8.37A; Bruker Axs Inc.: Madison, Wisconsin, USA, 2016.Suche in Google Scholar

2. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Suche in Google Scholar

3. Sheldrick, G. M. SHELXT – integrated space-group and crystal-structure determination. Acta Crystallogr. 2015, A71, 3–8; https://doi.org/10.1107/s2053273314026370.Suche in Google Scholar PubMed PubMed Central

4. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Suche in Google Scholar

5. Jaber, L. A., Bailey, E. M., Rybak, M. J. Enoxacin: a new fluoroquinolone. Clin. Pharm. 1989, 8, 97–107.Suche in Google Scholar

6. Rajendran, M. A., Allada, R., Sajid, S. S. Co-crystals for generic pharmaceuticals: an outlook on solid oral dosage formulations. Recent. Adv. Drug Deliv. Formul. 2021, 15, 15–36; https://doi.org/10.2174/2667387815666210203151209.Suche in Google Scholar PubMed

7. Karanam, M., Choudhury, A. R. Structural landscape of pure enrofloxacin and its novel salts: enhanced solubility for better pharmaceutical applicability. Cryst. Growth Des. 2013, 13, 1626–1637; https://doi.org/10.1021/cg301831s.Suche in Google Scholar

Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/ncrs-2022-0162).

Received: 2022-03-31
Accepted: 2022-05-16
Published Online: 2022-05-31
Published in Print: 2022-08-26

© 2022 Cheng-Jun Jiang and Ying-Fan Xia, published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of N-((3s,5s,7s)-adamantan-1-yl)-2-(3-benzoylphenyl)propanamide, C26H29NO2
  4. The crystal structure of bis(μ2-5-chloro-2-oxido-N-(1-oxidopropylidene)benzohydrazonato-κ5 N,O,O′:N′,O′′)-octakis(pyridine-κ1 N)trinickel(II) C60H56Cl2N12Ni3O6
  5. The crystal structure of 3-(4-chlorophenyl)-1,5-di-p-tolylpentane-1,5-dione, C25H23ClO2
  6. The crystal structure of 2,4,4-triphenyl-4H-benzo[b][1,4]oxaphosphinin-4-ium bromide – dichloromethane (1/1), C27H22BrCl2OP
  7. The crystal structure of 2-(3,6-di-tert-butyl-1,8-diiodo-9H-carbazol-9-yl)acetonitrile, C22H24I2N2
  8. Crystal structure of 3-phenylpropyl 2-(6-methoxynaphthalen-2-yl)propanoate, C23H24O3
  9. The crystal structure of (4-fluorophenyl)(5-(hydroxymethyl)furan-2-yl)methanol, C12H11FO3
  10. Crystal structure of the dihydrate of tetraethylammonium 1,3,5-thiadiazole-5-amido-2-carbamate, C11H27N5O4S
  11. Crystal structure of (Z)-4-[(p-tolylamino)(furan-2-yl)methylene]-3-phenyl-1-1-p-tolyl-1H-phenyl-1H-pyrazol-5(4H)-one, C28H23N3O2
  12. The crystal structure of (E)-3-(2-chlorophenyl)-1-ferrocenylprop-2-en-1-one, C19H15ClFeO
  13. The pseudosymmetric crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium hexachloridostannate(IV), C10H16N2SnCl6
  14. Crystal structure of (2-(1-hydroxyheptyl)octahydro-8aH-chromene-5,8,8a-triol), C16H30O5
  15. The crystal structure of N-cyclohexyl-3-hydroxy-4-methoxybenzamide, C14H19NO3
  16. Crystal structure of 1-(4-hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene-2,7-diol from Arundina graminifolia, C22H20O4
  17. The crystal structure of N-cyclopentyl-3-hydroxy-4-methoxybenzamide, C13H17NO3
  18. The crystal structure of 2,5,5-triphenyl-3,5-dihydro-4H-imidazol-4-one, C21H16N2O
  19. Crystal structure of 1H-1,2,3-Triazolo[4,5-b]-pyridin-4-ium nitrate, C5H5N5O3
  20. Crystal structure of (Z)-4-(((4-bromophenyl)amino)(furan-2-yl)methylene)-2,5-diphenyl-2,4-dihydro-3H-pyrazol-3-one, C26H18BrN3O2
  21. Crystal structure of 2-(4-methoxyphenyl)-3-methyl-1,8-naphthyridine, C16H14N2O
  22. The crystal structure of 3-([1,1′-biphenyl]-2-yl)-1,2-diphenylbenzo[b]phosphole-1-oxide, C32H23OP
  23. The crystal structure of ammonium (E)-4-((4-carboxyphenyl)diazenyl)benzoate, C14H13N3O4
  24. Crystal structure of bis(5-amino-1,2,4-triazol-4-ium-3-yl)methane sulfate, C5H10N8O4S
  25. The crystal structure of phenantroline-κ2 N,N′-bis(6-phenylpyridine-2-carboxylato-κ2 N,O)copper(II), C36H24N4O4Cu
  26. The crystal structure of tris(6-methylpyridin-2-yl)phosphine oxide, C18H18N3OP
  27. The crystal structure of N-(2′-hydroxymethyl-5′-phenyl-3′,4′-dihydro-[1,1′:3′,1″-terphenyl]- 1′(2′H)-yl)-P,P-diphenylphosphinic amide, C37H34NO2P
  28. Crystal structure of (E)-4-(6-(4-(2-(pyridin-4-yl)vinyl)phenoxy)pyrimidin-4-yl)morpholine, C21H20N4O2
  29. Crystal structure of 5-(adamantan-1-yl)-3-[(4-trifluoromethylanilino)methyl]-2,3-dihydro-1,3,4-oxadiazole-2-thione, C20H22F3N3OS
  30. Crystal structure of 2,2-dichloro-1-(4-chloro-1H-indol-1-yl)ethan-1-one, C10H6Cl3NO
  31. The crystal structure of 4-(((3-bromo-5-(trifluoromethyl)pyridin-2-yl)oxy)methyl)benzonitrile, C28H16Br2F6N4O2
  32. The crystal structure of 1H-benzimidazole-2-carboxamide, C8H7N3O
  33. The crystal structure of Histidinium hydrogensquarate, C10H11N3O6
  34. The crystal structure of 3-amino-5-carboxypyridin-1-ium iodide, C6H7IN2O2
  35. Crystal structure of (E)-amino(2-(3-ethoxy-4-hydroxybenzylidene)hydrazineyl)methaniminium nitrate hemihydrate C10H16N5O5.5
  36. Crystal structure of 1,2-bis(4,5-dinitro-1H-imidazol-1-yl)ethane, C8H6N8O8
  37. The crystal structure of diaqua-bis(pyrazolo[1,5-a]pyrimidine-3-carboxylato-κ2N,O)manganese(II), C14H12N6O6Mn
  38. The crystal structure of catena-poly[aqua-2,2′bipyridine-κ2N,N′-(μ2-5-ethoxyisophthalato-κ 4O,O:Oʺ,O′ʺ)cadmium(II)] monohydrate, C20H20CdN2O7
  39. The crystal structure of (1S,3R)-1-(4-isopropylphenyl)-3-(methoxycarbonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-iumchloride monohydrate, C22H27ClN2O3
  40. Crystal structure of 1-isopropyl-3-(prop-1-en-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, C11H15N5
  41. The crystal structure of (2,2′-bipyridine-κ2N,N′)- bis(6-phenylpyridine-2-carboxylate-κ2N,O)manganese(II)] monohydrate, C34H26N4O5Mn
  42. Crystal structure of the cocrystal 1,3,5,7-tetranitro-1,3,5,7-tetrazoctane ─ 2,3-dihydroindole (1/1), C12H17N9O8
  43. Crystal structure of 3-acetyl-6-hydroxy-2H-chromen-2-one monohydrate, C11H10O5
  44. Crystal structure of 6,9-diamino-2-ethoxyacridinium 3,5-dinitrobenozate — dimethylsulfoxide — water (1/1/1), C24H27N5O9S
  45. The crystal structure of 4,4′-bipyridinium bis-(2-hydroxy-3-methoxybenzoate), 2(C8H7.68O4)·C10H8.64N2
  46. Crystal structure of (Z)-4-(((4-fluorophenyl)amino)(furan-2-yl)methylene)-5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one
  47. The crystal structure of bis(4-chloro-2-(((2-chloroethyl)imino)methyl)phenolato-κ2N,O)-oxidovanadium(IV), C18H16Cl4N2O3V
  48. The crystal structure of 17-(bromoethynyl)-17-hydroxy-10, 13-dimethyl- 1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one, C21H27BrO2
  49. The crystal structure of 4-((6-fluoropyridin-2-yloxy)methyl)benzonitrile, C13H9FN2O
  50. Crystal structure of (Z)-2-(1-bromo-2-phenylvinyl)-5-ethyl-2-methyl-1,3-dioxane-5-carboxylic acid, C15H17Br1O4
  51. Crystal structure of catena-poly[tribenzyl-κ1C-(μ2-6-oxidopyridin-1-ium-3-carboxylato-κ2O:O’)tin(IV)-dichloromethane-methanol (1/1/1), C29H31Cl2NO4Sn
  52. Crystal structure of bis{2-(tert-butyl)-6-((E)-((4-((E)-1-(methoxyimino)ethyl)phenyl)imino)methyl)phenolato-κ2N,O}zinc(II), C40H46N4O4Zn
  53. Crystal structure of diaqua-bis(μ2-2-carboxy-3,4,5,6-tetrafluorobenzoato-κ2O:O′)-bis(phenanthroline-κ2N,N′)-bis(μ2-3,4,5,6-tetrafluorophthalato-κ3O:O,O′)dieuropium(III) – phenanthroline (1/2), C40H19EuF8N4O9
  54. The crystal structure of diaqua-bis(6-phenylpyridine-2-carboxylato-κ2N,O) manganese(II) — water — dimethylformamide (1/2/1), C27H31N3O9Mn
  55. The crystal structure of bis(pyrazolo[1,5-a]pyrimidine-3-carboxylato-κ2N,O)-copper(ii), C14H8N6O4Cu
  56. Crystal structure of poly[(μ2-1-(1-imidazolyl)-4-(imidazol-1-ylmethyl)benzene-κ2N:N′)-(μ3-pyridazine-4,5-dicarboxylate-κ3O:O′:N)]copper(II) hydrate, C19H16CuN6O5
  57. Crystal structure of acrinidinium tetrafluorohydrogenphthalate, C21H11F4NO4
  58. Crystal structure of 2-(1H-pyrazol-3-yl-κN)pyridine-κN-bis(2-(2,4-difluorophenyl)pyridinato-κ2C,N)iridium(III) sesquihydrate, C30H18F4IrN5·1.5[H2O]
  59. Crystal structure of 2-(2-hydroxy-5-nitrophenyl)-5-methyl-1,3-dioxane-5-carboxylic acid, C12H13N1O7
  60. The crystal structure of 1,2-bis(pyridinium-4-yl)ethane diperchlorate, C12H14N2·2ClO4 – a second polymorph
  61. The crystal structure of [(1,10-phenantroline-κ2N,N′)-bis(6-phenylpyridine-2-carboxylato-κ2N,O)manganese(II)] monohydrate, C36H26N4O5Mn
  62. Crystal structure of 1,2-bis(2,2,3,3,5,5,5-heptamethyl-1,1,4,4- tetrakis(trimethylsilyl)pentasilan-1-yl)ditellane, C38H114Si18Te2
  63. Crystal structure of 1,2-bis(2,4-dinitro-1H-imidazol-1-yl)ethane – dimethylformamide (1/1), C11H13N9O9
  64. Crystal structure of (Z)-3-((tert-butylamino) methylene)-2-(2-hydroxynaphthalen-1-yl) chroman-4-one, C24H23NO3
  65. Synthesis and crystal structure of (E)-1-(4-(((E)-3-(tert-butyl)-2-hydroxybenzylidene)amino)phenyl)ethan-1-one O-ethyl oxime, C21H26N2O2
  66. Crystal structure of the double salt bis(5-amino-1,2,4-triazol-4-ium-3-yl)methane hydrogen oxalate hemioxalate, C8H11N8O6
  67. Hydrothermal synthesis and crystal structure of catena-poly[diaqua-bis(μ2-4-[(4-pyridinylmethyl)amino]benzoato-κ2N:O)cobalt(II)]–1,2bi(4-pyridyl)ethene–water (1/1/1), C50H50N8O8Co
  68. Crystal structure of 3-(3-bromophenyl)-1′,3′-dimethyl-2′H,3H,4H-spiro[furo[3, 2-c]chromene-2,5′-pyrimidine]-2′,4,4′,6′(1′H,3′H) tetraone, C22H15BrN2O6
  69. The crystal structure of poly[aqua-(μ2-4,4′- bis(imidazolyl)biphenyl-κ2N:N′)-(μ2-3-nitrobenzene-1,2-dicarboxylato-κ2O:O′)]copper (II) hydrate, C26H21N5O8Cu
  70. The crystal structure of bis(4-(6-carboxy-8-ethyl-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2- yl)piperazin-1-ium) adipate tetrahydrate, C36H52F2N8O14
  71. Synthesis and crystal structure of poly[aqua(μ4-(1R,2S,4R)-4-hydroxy-1-((7-hydroxy-3-(4-hydroxy-3-sulfonatophenyl)-4-oxo-4H-chromen-8-yl)methyl)pyrrolidin-1-ium-2-carboxylate-κ4O:O′:O″:O‴)sodium(I)] monohydrate, C21H22NNaO12S
  72. Crystal structure of chlorido-(η6-toluene)(2,2′-bipyridine-κ2N,N′)ruthenium(II) hexafluorophosphate, C17H16ClN2RuPF6
  73. The crystal structure of (R)-6-hydroxy-8-methoxy-3-methylisochroman-1-one, C11H12O4
  74. Crystal structure of catena-poly[(5,5,7,12,12,14-hexamethyl -1,4,8,11-tetraazacyclotetradecane- κ4N,N′,Nʺ,N‴)nickel(II)-(μ2-perchlorato-κ2O:O′)] 3,5-dicarboxybenzoate – methanol (1/2), C27H49ClN4NiO12
  75. The crystal structure of 4-(chloromethyl)benzonitrile, C8H6ClN
  76. The crystal structure of dimethylammonium 8-[(7,9-dioxo-6,10-dioxaspiro[4.5]decan-8-ylidene)methyl]-9-oxo-6,10-dioxaspiro[4.5]dec-7-en-7-olate, C19H25NO8
  77. Crystal structure of (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-((1-acetyl-5-bromo-4-chloro-1H-indol-3-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate hemihydrate C24H25BrClNO11
  78. The crystal structure of the co-crystal tetrakis[2-(tris(4-methoxyphenyl)stannyl)ethyl]silane – tetrahydrofuran – toluene – tetrahydrofurane (1/1/1), C103H116O13SiSn4
  79. Crystal structure of methyl 3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propanoate, C16H13NO4
  80. Crystal structure of ethyl (Z)-3-amino-2-cyano-3-(2-oxo-2H-chromen-3-yl)acrylate, C15H12N2O4
  81. Crystal structure of methyl 2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)acetate, C15H11NO4
  82. Crystal structure of catena-poly[diaqua-bis(μ2-1,3-di(1H-imidazol-1-yl)propane-κ2N:N′)cobalt(II)] tetrafluoroterephthalate, C26H28N8O6F4Co
Heruntergeladen am 6.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2022-0162/html
Button zum nach oben scrollen